NASDAQ:AVTX Avalo Therapeutics (AVTX) Stock Price, News & Analysis $6.70 -0.43 (-6.03%) Closing price 11/18/2026 04:00 PM EasternExtended Trading$6.82 +0.12 (+1.79%) As of 07:26 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Avalo Therapeutics Stock (NASDAQ:AVTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Avalo Therapeutics alerts:Sign Up Key Stats Today's Range$6.68▼$7.1850-Day Range$6.63▼$17.1852-Week Range$6.53▼$24.27Volume1.58 million shsAverage Volume3.35 million shsMarket Capitalization$387.41 millionP/E RatioN/ADividend YieldN/APrice Target$36.82Consensus RatingModerate Buy Company Overview Avalo Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for immune-mediated and inflammatory diseases. The company does not have marketed products and is centered on advancing drug candidates through clinical development. Its lead candidate, AVTX-009, is a monoclonal antibody that targets interleukin-1 beta (IL-1β), an inflammatory signaling protein. Avalo is developing the therapy for hidradenitis suppurativa, a chronic inflammatory skin disease, and has described potential applications in other inflammatory conditions. Avalo was formerly known as Cerecor Inc. The company’s current focus reflects a shift toward inflammatory disease research, with its development efforts concentrated on AVTX-009.AI Generated. May Contain Errors. Read More Avalo Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks79th Percentile Overall ScoreAVTX MarketRank™: 3.973849945235 of 5 starsAvalo Therapeutics scored higher than 79% of companies evaluated by MarketBeat, and ranked 191st out of 1,704 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingAvalo Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on no strong buy ratings, 11 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialAvalo Therapeutics has a consensus price target of $36.82, representing about 449.5% upside from its current price of $6.70.Amount of Analyst CoverageAvalo Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Avalo Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Avalo Therapeutics are expected to grow in the coming year, from ($2.52) to ($2.15) per share.Price to Book Value per Share RatioAvalo Therapeutics has a P/B Ratio of 0.89. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted17.30% of the float of Avalo Therapeutics has been sold short.Short Interest Ratio / Days to CoverAvalo Therapeutics has a short interest ratio ("days to cover") of 2.09, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Avalo Therapeutics has recently decreased by 25.52%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAvalo Therapeutics does not currently pay a dividend.Dividend GrowthAvalo Therapeutics does not have a long track record of dividend growth. News and Social Media2.0 / 5News Sentiment0.27 News SentimentAvalo Therapeutics has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Avalo Therapeutics this week, compared to 4 articles on an average week.Search Interest6 people have searched for AVTX on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Avalo Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $395,434.00 in company stock.Percentage Held by Insiders4.46% of the stock of Avalo Therapeutics is held by insiders.Percentage Held by Institutions87.06% of the stock of Avalo Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Avalo Therapeutics' insider trading history. Receive AVTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avalo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AVTX Stock News HeadlinesAvalo Therapeutics (AVTX) vs. The Competition Financial SurveyNovember 18 at 3:44 AM | americanbankingnews.comAvalo Therapeutics (AVTX) Gets a Buy from BTIGNovember 14, 2026 | theglobeandmail.comYou missed yesterday's deadline…In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.November 19 at 1:00 AM | Behind the Markets (Ad)HC Wainwright Has Bullish Estimate for AVTX FY2026 EarningsNovember 12, 2026 | americanbankingnews.comWedbush Issues Pessimistic Forecast for Avalo Therapeutics (NASDAQ:AVTX) Stock PriceNovember 8, 2026 | americanbankingnews.comAvalo Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business UpdatesNovember 5, 2026 | globenewswire.comAvalo Therapeutics to Participate in Upcoming Investor ConferencesNovember 2, 2026 | globenewswire.comAvalo Therapeutics consensus price target decreased by 19.84% to $36.72November 2, 2026 | msn.comSee More Headlines AVTX Stock Analysis - Frequently Asked Questions How have AVTX shares performed this year? Avalo Therapeutics' stock was trading at $18.16 at the start of the year. Since then, AVTX stock has decreased by 63.1% and is now trading at $6.70. How were Avalo Therapeutics' earnings last quarter? Avalo Therapeutics, Inc. (NASDAQ:AVTX) released its quarterly earnings results on Thursday, November, 5th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.59) by $0.25. When did Avalo Therapeutics' stock split? Avalo Therapeutics shares reverse split on the morning of Friday, December 29th 2023.The 1-240 reverse split was announced on Friday, December 29th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, December 29th 2023. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split. Who are Avalo Therapeutics' major shareholders? Avalo Therapeutics' top institutional investors include State Street Corp (4.43%), Nantahala Capital Management LLC (3.71%), Goldman Sachs Group Inc. (1.28%) and Soleus Capital Management L.P. (0.66%). Insiders that own company stock include Mittie Doyle, Christopher Ryan Sullivan, Paul Varki and June Sherie Almenoff. View institutional ownership trends. How do I buy shares of Avalo Therapeutics? Shares of AVTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Avalo Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Avalo Therapeutics investors own include Energy Transfer (ET), Definium Therapeutics (DFTX), Cybin (HELP), Novo Integrated Sciences (NVOS), Palantir Technologies (PLTR), Riot Platforms (RIOT) and IonQ (IONQ). Company Calendar Last Earnings11/05/2026Today11/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (4w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 4 weeks, AVTX's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:AVTX CIK1534120 Webwww.avalotx.com Phone(410) 522-8707FaxN/AEmployees33Year Founded2015Price Target and Rating Average Price Target for Avalo Therapeutics$36.82 High Price Target$60.00 Low Price Target$10.00 Potential Upside/Downside+449.5%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage14 Analysts Profitability EPS (Trailing Twelve Months)($2.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$78.26 million Net MarginsN/A Pretax Margin-149,976.28% Return on Equity-34.21% Return on Assets-29.84% Debt Debt-to-Equity RatioN/A Current Ratio16.63 Quick Ratio16.63 Sales & Book Value Annual Sales$60 thousand Price / Sales6,456.57 Cash FlowN/A Price / Cash FlowN/A Book Value$7.55 per share Price / Book0.89Miscellaneous Outstanding Shares57,820,000Free Float55,244,000Market Cap$387.39 million OptionableOptionable Beta0.75 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:AVTX) was last updated on 11/18/2026 by MarketBeat.com Staff. From Our PartnersYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | Sponsored432 miles southeast of Washington, DC…Spruce Pine, North Carolina, a town of just over 2,000 people, has supplied a material to every major chip mak...Wall Street Watchdogs | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avalo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avalo Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.